Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2023 | Frontline endocrine therapies and ribociclib in early stage HR+ HER2- breast cancer

Eva Ciruelos • 16 Mar 2023
BCC 2023
Breast Cancer Ribociclib
RIGHT Choice

Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, discusses the use of frontline CDK4/6 inhibitors in combination with endocrine therapy for the treatment of early-stage HR+/HER2- breast cancer. Dr Ciruelos highlights results from the RIGHT Choice trial which suggests that first-line ribociclib plus endocrine therapy can be an efficacious treatment for patients with aggressive, advanced breast cancer. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eva Ciruelos

ELECTRA: elacestrant and abemaciclib in patients with ER+, HER2- breast cancer
1:43
ELECTRA: elacestrant and abemaciclib in patients with ER+, HER2- breast cancer
Eva Ciruelos • 15 Sep 2024
ELECTRA: novel combinations for HR-positive breast cancer with CNS metastases
0:42
ELECTRA: novel combinations for HR-positive breast cancer with CNS metastases
Eva Ciruelos • 15 Sep 2024
DESTINY-Breast12: enhancing outcomes for HR+/HER2+ patients with brain metastases
1:33
DESTINY-Breast12: enhancing outcomes for HR+/HER2+ patients with brain metastases
Eva Ciruelos • 15 Sep 2024
Global collaboration in biomarker-driven clinical trials at ESMO 2024
1:03
Global collaboration in biomarker-driven clinical trials at ESMO 2024
Eva Ciruelos • 15 Sep 2024

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals